Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
A Randomized Phase II Study Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Nathan Neufeld, DO
- Phone Number: 770-400-6035
- Email: nathan.neufeld@ctca-hope.com
Study Contact Backup
- Name: Ricardo Alvarez, MD
- Phone Number: 770-400-6633
- Email: ricardo.alvarez@ctca-hope.com
Study Locations
-
-
Georgia
-
Newnan, Georgia, United States, 30265
- Cancer Treatment Centers of America - Atlanta
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has a diagnosis of invasive colorectal cancer, locally advanced or advanced, requiring oxaliplatin-based chemotherapy for treatment.
- Subject has agreed to receive treatment at Cancer Treatment Centers of America, Southeastern Regional Medical Center.
- Subject is Male or Female
- Subject is 18 years of age or older.
- Subject is a patient who reports neurotoxicity symptom grade 2 or more according CTCAE criteria to his or her medical oncologist following one or more cycles of oxaliplatin-based chemotherapy treatment.
- Subject is a patient who is capable and accepting of completing study questionnaires at each data collection point.
- Subject has adequate English fluency for completion of data collection. The surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
- Subject must have the ability to understand and the willingness to sign a written informed consent
- Subject must be willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Subjects who have previously been exposed to neurotoxic agents including pyridoxine (>100 mg/day), colchicine, allopurinol, or phenytoin;
- Subjects with pre-existing comorbidities, such as: diabetes, uremia, significant peripheral vascular disease, HIV, or progressive or degenerative neurologic disorders (e.g., multiple sclerosis, B12 deficiency); cardiovascular valve disease, history of cardiovascular event,
- Subjects with a history of lumbosacral laminectomy or radiculopathy;
- Subjects who have been prescribed and taken gabapentin, pregabalin, or duloxetine currently or within the last 1 months)
- Subjects who have established or suspected family history of inherited neuropathy.
- Subjects unable to swallow indicated medication
- Subjects in general with a medical condition, laboratory finding, or physical exam finding that precludes participation
- Subject weight of ≥350 lbs.
- Subjects who currently use disallowed concomitant medications
- Subjects with any form of cardiac implants
- Subjects who report recent febrile illness that precludes or delays participation
- Subjects with pregnancy or lactation
- Subjects with known allergic reactions to components of the study product(s)
- Subjects receiving treatment with another investigational drug or other intervention
- Subjects with a history of or current tobacco or illegal substance use
- Subjects exhibiting significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Control
Duloxetine 60 mg qd
|
60 mg tablet Taken by mouth, Once Daily for 180 Days
|
|
EXPERIMENTAL: Intervention
Lorcaserin 10 mg bid
|
10 mg tablet Taken by mouth Twice Daily for 180 Days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment with respect to duloxetine of the effect of lorcaserin on the Pain Numerical Rating Scale.
Time Frame: 180 days
|
Duloxetine efficacy as Measured by Pain Score 0-10 Numerical Rating Scale.
Subject will rate level of pain experienced from 0 (No Pain) to 10 (Worst Possible Pain) for each question on the Brief Pain Inventory Short Form.
A rating of 5 would be Moderate Pain.
|
180 days
|
|
Assessment with respect to duloxetine of the effect of lorcaserin on the patient-reported quality of life.
Time Frame: 180 days
|
Subject quality of life will be measured using the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group-Neurotoxocity (FACT/GOG-NTX) Questionnaire.
For each statement, the subject will answer 0-5 with 0 being "Not at All" and 5 being "Very Much"
|
180 days
|
|
Assessment with respect to duloxetine of the effect of lorcaserin on the patient-reported quality of life.
Time Frame: 180 days
|
Subject quality of life will also be measured using the MD Anderson Symptom Inventory (MDASI) Questionnaire, with CTCA addendum.
For each statement, the subject will answer from 0-10, with 0 being "Not Present" and 10 being "As Bad as You Can Imagine)
|
180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- SA2018005 LVD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.